Sarcoma, Soft Tissue

Retroperitoneal Neoplasms

Surgery

Quality of Life

Morbidity

Long Term Morbidity and Quality of Life in Retroperitoneal Sarcomas

Long Term Morbidity and Quality of Life After Multivisceral Resection for Primary Retroperitoneal Soft Tissue Sarcomas: a Prospective Observational Study

Change between baseline and 4 and 12 months scores of the "global health status / QoL" scale in patients primarily treated for localized RSTS, as determined in QLQ-C30 version 3.0.

Evaluate the long term morbidity of aggressive surgical approach to RSTS in terms of renal failure.

Change between baseline and 4 and 12 months scores

Marco Fiore

Attending Surgeon

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.

20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.

Myofascial Pain Syndromes

Myofascial Trigger Point Pain

Trigger Point Pain, Myofascial

comparison of OnabotulinumtoxinA with placebo

OnabotulinumtoxinA

comparison of placebo with investigational drug OnabotulinumtoxinA

Placebo

University Case Medical Center

University Hospitals Landerbrook Health Center, Urology

University Hospitals Westlake Health Center, Urology

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

Pelvic Floor Trigger Point Injection With OnabotulinumtoxinA for the Treatment of Severe Myofascial Pelvic Pain (MPP) - A Randomized, Controlled Trial

a 30% reduction of pain and muscular spasm assessed by visual analog scale - VAS

Reduction of pain and muscular spasm assessed at the 1 month visit by visual analog scale - VAS

assessed by validated patient-filled questionnaires

Assessed by clinical complications of therapy (including urinary retention by PVR and other associated complaints)

assessed by pelvic pain scores and pelvic floor pressures

assessed by pelvic pain scores after injection and/or by a change in treatment

assessed by urinary retention defined (PVR >150ml) and other associated complaints

Sangetta Mahajan MD

Assistant Professor & Head Division of Female Pelvic Medicine/Reconstructive Surgery/Obstetrics/Gynecology/Urology and Director of joint fellowship in Female Pelvic Medicine andReconstructive Surgery in the Departments of Obstetrics/Gynecology/Urology

dyspareunia/oksendamine

Long Term Morbidity and Quality of Life in Retroperitoneal Sarcomas

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus